Please assess the completion status of the following clinical trial:

Trial Title: Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria:~* male or female subjects of any race, ages 18-75 inclusive, with a clinical diagnosis of Bipolar I or Bipolar II disorder~* experiencing a current major depressive episode~* able to provide written informed consent~Major Exclusion Criteria:~* any female subject who is pregnant or breast-feeding~* any subject judged to be medically inappropriate for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lumateperone (Type: EXPERIMENTAL): Lumateperone 42 mg (ITI-007 60 mg tosylate) administered once daily every evening for 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered once daily every evening for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).